About Immunovant, Inc.
https://immunovant.comImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
CEO
Eric Venker
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B of A Securities
Buy
Guggenheim
Buy
JP Morgan
Overweight
Goldman Sachs
Neutral
UBS
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:14.73M
Value:$402.85M
DEEP TRACK CAPITAL, LP
Shares:9.73M
Value:$266.08M
VANGUARD GROUP INC
Shares:6.83M
Value:$186.71M
Summary
Showing Top 3 of 217
About Immunovant, Inc.
https://immunovant.comImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $0 | $131.76M ▲ | $-126.5M ▼ | 0% | $-0.73 ▼ | $-131.66M ▼ |
| Q1-2026 | $0 | $127.22M ▲ | $-120.61M ▼ | 0% | $-0.71 ▼ | $-127.12M ▼ |
| Q4-2025 | $0 | $113.83M ▼ | $-106.45M ▲ | 0% | $-0.64 ▲ | $-113.72M ▲ |
| Q3-2025 | $0 | $114.3M ▼ | $-111.12M ▼ | 0% | $-0.76 ▼ | $-114.2M ▲ |
| Q2-2025 | $0 | $115.74M | $-109.12M | 0% | $-0.74 | $-115.65M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $521.87M ▼ | $582.96M ▼ | $63.25M ▲ | $519.71M ▼ |
| Q1-2026 | $598.91M ▼ | $661.44M ▼ | $52.9M ▼ | $608.54M ▼ |
| Q4-2025 | $713.97M ▲ | $776.22M ▲ | $68.78M ▲ | $707.45M ▲ |
| Q3-2025 | $374.69M ▼ | $420.93M ▼ | $68.31M ▲ | $352.62M ▼ |
| Q2-2025 | $472.94M | $515.71M | $66.65M | $449.05M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $-126.5M ▼ | $-102.52M ▲ | $0 | $24.59M ▲ | $-77.04M ▲ | $-102.52M ▲ |
| Q1-2026 | $-120.61M ▼ | $-117.41M ▼ | $0 ▲ | $2.92M ▼ | $-115.06M ▼ | $-117.41M ▼ |
| Q4-2025 | $-106.45M ▲ | $-110.64M ▼ | $-201K ▼ | $450.61M ▲ | $339.29M ▲ | $-110.84M ▼ |
| Q3-2025 | $-111.12M ▼ | $-100.39M ▼ | $-180K ▲ | $2.46M ▲ | $-98.26M ▼ | $-100.57M ▼ |
| Q2-2025 | $-109.12M | $-88.65M | $-196K | $730K | $-87.06M | $-88.84M |
CEO
Eric Venker
Compensation Summary
(Year 2025)
ETFs Holding This Stock
Summary
Showing Top 3 of 123
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
B of A Securities
Buy
Guggenheim
Buy
JP Morgan
Overweight
Goldman Sachs
Neutral
UBS
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:14.73M
Value:$402.85M
DEEP TRACK CAPITAL, LP
Shares:9.73M
Value:$266.08M
VANGUARD GROUP INC
Shares:6.83M
Value:$186.71M
Summary
Showing Top 3 of 217